Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2022; 28(31): 4299-4309
Published online Aug 21, 2022. doi: 10.3748/wjg.v28.i31.4299
Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction
Yi-Han Zheng, En-Hao Zhao
Yi-Han Zheng, En-Hao Zhao, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
Author contributions: Zheng YH wrote the manuscript; Zhao EH reviewed and revised the manuscript; and both authors proofed the manuscript.
Conflict-of-interest statement: The authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: En-Hao Zhao, PhD, Associate Professor, Doctor, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160 Pujian Road, Shanghai 200127, China. microzhaoenhao@hotmail.com
Received: January 17, 2022
Peer-review started: January 17, 2022
First decision: March 8, 2022
Revised: March 22, 2022
Accepted: July 20, 2022
Article in press: July 20, 2022
Published online: August 21, 2022
Abstract

Esophageal adenocarcinoma (EAC) and adenocarcinoma of the esophagogastric junction (EGJA) have long been associated with poor prognosis. With changes in the spectrum of the disease caused by economic development and demographic changes, the incidence of EAC and EGJA continues to increase, making them worthy of more attention from clinicians. For a long time, surgery has been the mainstay treatment for EAC and EGJA. With advanced techniques, endoscopic therapy, radiotherapy, chemotherapy, and other treatment methods have been developed, providing additional treatment options for patients with EAC and EGJA. In recent decades, the emergence of multidisciplinary therapy (MDT) has enabled the comprehensive treatment of tumors and made the treatment more flexible and diversified, which is conducive to achieving standardized and individualized treatment of EAC and EGJA to obtain a better prognosis. This review discusses recent advances in EAC and EGJA treatment in the surgical-centered MDT mode in recent years.

Keywords: Multidisciplinary therapy, Esophageal adenocarcinoma, Adenocarcinoma of esophagogastric junction, Endoscopic resection, Surgery

Core Tip: Worldwide, esophageal adenocarcinoma (EAC) and adenocarcinoma of the esophagogastric junction (EGJA) have long been associated with poor prognosis, and their incidence continues to increase. For a long time, surgery has been the mainstay treatment for EAC and EGJA. With the advent of advanced techniques, other treatment methods have been developed. In recent decades, the emergence of multidisciplinary therapy (MDT) has enabled the comprehensive treatment of tumors, which is conducive to achieving standardized and individualized treatment. This review discusses recent advances in EAC and EGJA treatment in the surgical-centered MDT mode in recent years.